Previous 10 | Next 10 |
Verve Therapeutics press release (NASDAQ:VERV): Q4 GAAP EPS of -$0.65 misses by $0.12. Cash, Cash Equivalents and Marketable Securities of $360.4 Million with Cash Runway into 2024 For further details see: Verve Therapeutics GAAP EPS of -$0.65 misses by $0.12
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing Approach and Proprietary Lipid Nanoparticle Delivery System ...
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
ARK Invest has published their main investment themes for each year since 2017, including numerical projections for how these themes will grow and outperform. I checked how accurate their 2017 projections were over the last five years and was surprised by what I found. I also look...
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will...
Verve Therapeutics (NASDAQ:VERV) appointed Allison Dorval as its new CFO; Ms. Dorval joins Verve from Voyager Therapeutics and brings 20+ years of leadership experience in finance, accounting, financial reporting and investor relations. "Her extensive experience leading finance func...
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief fin...
Gainers: Pasithea Therapeutics (NASDAQ:KTTA) +257%, Petros Pharmaceuticals (NASDAQ:PTPI) +73%, Gracell Biotechnologies (NASDAQ:GRCL) +64%, iSpecimen (NASDAQ:ISPC) +43%, Qualigen Therapeutics (NASDAQ:QLGN) +33%. Losers: Longeveron (NASDAQ:LGVN) -36%...
Verve Therapeutics (NASDAQ:VERV): Q3 GAAP EPS of -$0.47 beats by $0.05. Cash, cash equivalents and marketable securities were $389.2M as of September 30, 2021 Press Release For further details see: Verve Therapeutics EPS beats by $0.05
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...